Truist raised the firm’s price target on Penumbra (PEN) to $285 from $240 and keeps a Buy rating on the shares as part of a broader research note previewing 2025 in Medical Technology. The firm sees the sector as “one of the better/safer houses” in healthcare given its lower “front-line” exposure to healthcare policy rhetoric that is tied to the administration change as well as its position as an “innovation segment” with sustainable above-average revenue and EPS growth, strong balance sheets, and healthy free cash flows. Truist adds that it prefers small-mid size companies over large caps as M&A may be “poised to heat up”.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PEN:
- Penumbra initiated with an Outperform at Oppenheimer
- Reddit initiated, GE Vernova downgraded: Wall Street’s top analyst calls
- Penumbra price target raised to $245 from $220 at Citi
- Penumbra upgraded to Overweight from Equal Weight at Wells Fargo
- Penumbra price target raised to $323 from $260 at Canaccord